Targeting Inflammation in Atherosclerosis - from Experimental Insights to the Clinic

Overview

Journal Nat Rev Drug Discov

Specialty Pharmacology

Date 2021 May 12

PMID 33976384

Citations 353

Authors

Oliver Soehnlein

Peter Libby

Affiliations

Soon will be listed here.

Abstract

Atherosclerosis, a dominant and growing cause of death and disability worldwide, involves inflammation from its inception to the emergence of complications. Targeting inflammatory pathways could therefore provide a promising new avenue to prevent and treat atherosclerosis. Indeed, clinical studies have now demonstrated unequivocally that modulation of inflammation can forestall the clinical complications of atherosclerosis. This progress pinpoints the need for preclinical investigations to refine strategies for combatting inflammation in the human disease. In this Review, we consider a gamut of attractive possibilities for modifying inflammation in atherosclerosis, including targeting pivotal inflammatory pathways such as the inflammasomes, inhibiting cytokines, manipulating adaptive immunity and promoting pro-resolution mechanisms. Along with lifestyle measures, pharmacological interventions to mute inflammation could complement traditional targets, such as lipids and hypertension, to make new inroads into the management of atherosclerotic risk.

Citing Articles

Maternal high-fat diet exacerbates atherosclerosis development in offspring through epigenetic memory.

Li K, Qian W, Zhang F, Zhang W, Lv H, Quan M Nat Cardiovasc Res. 2025; .

PMID: 40087523 DOI: 10.1038/s44161-025-00622-4.

High-Density Lipoprotein Biomimetic Inorganic-Organic Composite Nanosystem for Atherosclerosis Therapy.

Zhang Y, Liu D, Wang Y, Sun Q, Mei D, Wang X Polymers (Basel). 2025; 17(5).

PMID: 40076117 PMC: 11902788. DOI: 10.3390/polym17050625.

Dissecting Causal Relationship Among Immune Cells, Plasma Metabolites and Coronary Atherosclerosis: A Mendelian Randomization Study.

Cao Q, Liu J, Sun J, Qian S, Song J, Zheng H Immunotargets Ther. 2025; 14:175-188.

PMID: 40066076 PMC: 11892494. DOI: 10.2147/ITT.S508042.

High-Sensitivity CRP and Occurrence of Cancer in Cardiovascular Disease Patients with Cardiovascular.

de la Brassinne Bonardeaux O, Deneye M, Oury C, Moonen M, Lancellotti P J Clin Med. 2025; 14(4).

PMID: 40004724 PMC: 11856179. DOI: 10.3390/jcm14041193.

The Crosstalk Between Endothelial Cells, Smooth Muscle Cells, and Macrophages in Atherosclerosis.

Gong S, Li Y, Yan K, Shi Z, Leng J, Bao Y Int J Mol Sci. 2025; 26(4).

PMID: 40003923 PMC: 11855868. DOI: 10.3390/ijms26041457.

References

Roth G, Mensah G, Johnson C, Addolorato G, Ammirati E, Baddour L . Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020; 76(25):2982-3021. PMC: 7755038. DOI: 10.1016/j.jacc.2020.11.010. View

Ridker P, Everett B, Thuren T, MacFadyen J, Chang W, Ballantyne C . Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017; 377(12):1119-1131. DOI: 10.1056/NEJMoa1707914. View

Tardif J, Kouz S, Waters D, Bertrand O, Diaz R, Maggioni A . Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019; 381(26):2497-2505. DOI: 10.1056/NEJMoa1912388. View

Nidorf S, Fiolet A, Mosterd A, Eikelboom J, Schut A, Opstal T . Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020; 383(19):1838-1847. DOI: 10.1056/NEJMoa2021372. View

Gimbrone Jr M, Garcia-Cardena G . Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res. 2016; 118(4):620-36. PMC: 4762052. DOI: 10.1161/CIRCRESAHA.115.306301. View

Sage A, Tsiantoulas D, Binder C, Mallat Z . The role of B cells in atherosclerosis. Nat Rev Cardiol. 2018; 16(3):180-196. DOI: 10.1038/s41569-018-0106-9. View

Gistera A, Hansson G . The immunology of atherosclerosis. Nat Rev Nephrol. 2017; 13(6):368-380. DOI: 10.1038/nrneph.2017.51. View

Basatemur G, Jorgensen H, Clarke M, Bennett M, Mallat Z . Vascular smooth muscle cells in atherosclerosis. Nat Rev Cardiol. 2019; 16(12):727-744. DOI: 10.1038/s41569-019-0227-9. View

Skalen K, Gustafsson M, Rydberg E, Mattsson Hulten L, Wiklund O, Innerarity T . Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 2002; 417(6890):750-4. DOI: 10.1038/nature00804. View

10.

Cushing S, Berliner J, Valente A, Territo M, Navab M, Parhami F . Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A. 1990; 87(13):5134-8. PMC: 54276. DOI: 10.1073/pnas.87.13.5134. View

11.

Quinn M, Parthasarathy S, Fong L, Steinberg D . Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A. 1987; 84(9):2995-8. PMC: 304787. DOI: 10.1073/pnas.84.9.2995. View

12.

Soehnlein O, Drechsler M, Doring Y, Lievens D, Hartwig H, Kemmerich K . Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes. EMBO Mol Med. 2013; 5(3):471-81. PMC: 3598085. DOI: 10.1002/emmm.201201717. View

13.

Cherepanova O, Gomez D, Shankman L, Swiatlowska P, Williams J, Sarmento O . Activation of the pluripotency factor OCT4 in smooth muscle cells is atheroprotective. Nat Med. 2016; 22(6):657-65. PMC: 4899256. DOI: 10.1038/nm.4109. View

14.

Misra A, Feng Z, Chandran R, Kabir I, Rotllan N, Aryal B . Integrin beta3 regulates clonality and fate of smooth muscle-derived atherosclerotic plaque cells. Nat Commun. 2018; 9(1):2073. PMC: 5970166. DOI: 10.1038/s41467-018-04447-7. View

15.

Jaiswal S, Natarajan P, Silver A, Gibson C, Bick A, Shvartz E . Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2017; 377(2):111-121. PMC: 6717509. DOI: 10.1056/NEJMoa1701719. View

16.

Murry C, Gipaya C, Bartosek T, BENDITT E, Schwartz S . Monoclonality of smooth muscle cells in human atherosclerosis. Am J Pathol. 1997; 151(3):697-705. PMC: 1857839. View

17.

Durgin B, Cherepanova O, Gomez D, Karaoli T, Alencar G, Butcher J . Smooth muscle cell-specific deletion of unexpectedly leads to impaired development of advanced atherosclerotic lesions. Am J Physiol Heart Circ Physiol. 2017; 312(5):H943-H958. PMC: 5451587. DOI: 10.1152/ajpheart.00029.2017. View

18.

Langley S, Willeit K, Didangelos A, Matic L, Skroblin P, Barallobre-Barreiro J . Extracellular matrix proteomics identifies molecular signature of symptomatic carotid plaques. J Clin Invest. 2017; 127(4):1546-1560. PMC: 5373893. DOI: 10.1172/JCI86924. View

19.

Vengrenyuk Y, Nishi H, Long X, Ouimet M, Savji N, Martinez F . Cholesterol loading reprograms the microRNA-143/145-myocardin axis to convert aortic smooth muscle cells to a dysfunctional macrophage-like phenotype. Arterioscler Thromb Vasc Biol. 2015; 35(3):535-46. PMC: 4344402. DOI: 10.1161/ATVBAHA.114.304029. View

20.

Shankman L, Gomez D, Cherepanova O, Salmon M, Alencar G, Haskins R . KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat Med. 2015; 21(6):628-37. PMC: 4552085. DOI: 10.1038/nm.3866. View